



**Keykavous Parang, Pharm.D., Ph.D.**

Professor of Medicinal Chemistry and Pharmacology



Dr. Parang holds the position of Full Professor in Medicinal Chemistry and Pharmacology at Chapman University School of Pharmacy situated in Irvine, California. Additionally, he maintains a dual role as a faculty member within the Department of Chemistry and Biochemistry at the Schmid College of Science and Technology, also part of Chapman University. In a collaborative capacity, Dr. Parang contributes his expertise as an affiliate volunteer faculty member, specifically as a Project Scientist Step III, within the division of Nephrology and Hypertension in the Department of Medicine at the University of California, Irvine. Dr. Parang's academic journey includes earning his Ph.D. in medicinal chemistry from the Faculty of Pharmacy at the University of Alberta in 1997. Following this, he embarked on a postdoctoral study focusing on solid-phase organic synthesis within the Department of Chemistry. He furthered his postdoctoral studies in bioorganic chemistry, undertaking research at Rockefeller University in New York and Johns Hopkins University in Baltimore. His tenure at the University of Rhode Island commenced in October 2000, where he subsequently ascended to the rank of full professor in July 2008. During his time there, he undertook the role of Program Coordinator for the Rhode Island IDeA Network of Biomedical Research Excellence (RI-INBRE) NIH program from 2012 to 2013. Dr. Parang's contributions to the academic community are evidenced by his authorship of 231 peer-reviewed publications, 23 patents or patent applications, and 197 meeting abstracts. His research pursuits converge at the dynamic crossroads of chemistry and biology, with a particular emphasis on medicinal chemistry, organic chemistry, nanomedicine, and drug delivery. His research activities encompass:

1. Devising Peptides as Agents Against Bacterial and Fungal Infections.
2. Leveraging Peptide Nanomaterials for the Advancement of Drug Delivery.
3. Innovating Inhibitors for Protein Tyrosine Kinases.
4. Pioneering the Development of Multifunctional Antiviral Agents.